Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) patients. Osimertinib is an effective therapy for NSCLC patients with acquired resistance due to T790M mutation after first- and...

Full description

Bibliographic Details
Main Authors: Ping-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Chiao-En Wu
Format: Article
Language:English
Published: SAGE Publishing 2022-10-01
Series:Therapeutic Advances in Respiratory Disease
Online Access:https://doi.org/10.1177/17534666221132731

Internet

https://doi.org/10.1177/17534666221132731

Similar Items